CurveBeam AI Ltd (ASX:CVB): China Expansion Plans Supported by Capital Raising

Aditi Sarkar

23 September 2026 04:38 PM AEST

CurveBeam AI Ltd (ASX:CVB): China Expansion Plans Supported by Capital Raising

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CurveBeam AI completed a Shortfall Offer and Placement raising A$1.75 million to support expansion activities.
The company develops specialised CT imaging equipment and AI-enabled SaaS clinical assessment solutions.
Funds raised are planned for sales and marketing, product enhancements, Supply chain preparation and working capital.
CurveBeam AI (ASX:CVB) continues commercial activities across China, the United States and other international markets.

At the time of writing this article, CurveBeam AI Ltd (ASX:CVB) was trading at approximately A$0.030 during today’s trading session, reflecting a daily movement of around 7.14%. The company is being reviewed following its latest announcement regarding a capital raising initiative designed to support expansion activities, including preparation for the China market launch of its medical imaging technology.

Company Business

CurveBeam AI develops, manufactures and sells specialised medical imaging CT scanners combined with AI SaaS-based clinical assessment solutions. The company focuses on supporting medical practitioners managing musculoskeletal conditions through advanced imaging technology. Its flagship HiRise™ CT scanner is designed to perform both weight-bearing and non-weight-bearing CT scans, providing imaging capabilities for clinical applications.

CurveBeam AI operates across Australia and the United States, with corporate, AI and intellectual property functions located in Melbourne and global operations headquarters in Pennsylvania. The company has more than 70 employees supporting its technology and commercial activities.

Recent Development

In September 2026, CurveBeam AI announced the results of its Share Purchase Plan Shortfall Offer and placement, securing A$1.75 million in additional funding. The company accepted A$1.39 million through the Shortfall Offer and A$0.36 million through a placement at A$0.018 per share.

The company stated that the funds will contribute towards sales and Marketing expenses, including China market launch preparation for HiRise™, Research and Development activities, product enhancements, supply chain preparation and Working Capital requirements.

CurveBeam AI also highlighted the recent FDA 510(k) clearance of its CT-based Bone Mineral Density technology, which the company said supports further development of bone quality assessment capabilities across its imaging platforms.

Financial Performance and Sector Context

The latest announcement focused on capital raising activities rather than financial results. CurveBeam AI raised total funds of A$7.36 million through a combination of a A$5 million placement, a A$0.61 million Share Purchase Plan and the A$1.75 million Shortfall Offer and placement.

The medical imaging sector continues to see developments around digital healthcare technologies, artificial intelligence applications and specialised diagnostic solutions. Companies operating in this segment may be influenced by regulatory approvals, commercial adoption, healthcare spending patterns and product development requirements.

Risks to Consider

Key risks include delays in commercial expansion, regulatory requirements across different markets, product development costs, supply chain challenges and the pace of adoption of specialised medical imaging technologies. The company’s international expansion activities may also require continued Investment in sales, marketing and operational infrastructure.

What to Watch Next

Future developments to monitor include progress on CurveBeam AI’s China market launch preparation, commercial activities across international markets, further product enhancements for HiRise™, and updates regarding the company’s medical imaging technology initiatives.

Key Insights

CurveBeam AI is focused on specialised medical imaging and AI-enabled clinical assessment solutions, with recent funding directed towards expansion and operational activities. The company’s upcoming developments will include commercial execution, product advancement and progress across international markets.

FAQs

Q:What does CurveBeam AI develop?

A:CurveBeam AI develops specialised medical imaging CT scanners and AI-enabled SaaS-based clinical assessment solutions.

Q:What was the purpose of the recent capital raising?

A:The company raised funds to support activities including China market preparation, product enhancements, supply chain preparation and working capital.

Q:What is HiRise™?

A:HiRise™ is CurveBeam AI’s flagship CT scanner designed for weight-bearing and non-weight-bearing CT scans.

Q:Where does CurveBeam AI operate?

A:The company has corporate and AI functions in Melbourne, Australia, and global operations headquarters in Pennsylvania, United States.

Q:What developments may be monitored next?

A:Future updates may include commercial expansion activities, product development progress and operational milestones.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.